A randomized phase II clinical trial of tailored CPT-11 + S-1 vs S-1 in patients with advanced or recurrent gastric carcinoma as the first line chemotherapy

Yutaka Takahashi; Junichi Sakamoto; Tetsuo Takeuchi; Masayoshi Mai; Tetsuro Kubota; Masaki Kitajima; Yusuke Tanigawara; Yoshito Komatsu; Tetsuya Toge; Shigetoyo Saji

doi:10.1093/jjco/hyh067

A randomized phase II clinical trial of tailored CPT-11 + S-1 vs S-1 in patients with advanced or recurrent gastric carcinoma as the first line chemotherapy

Yutaka Takahashi, Junichi Sakamoto, Tetsuo Takeuchi, Masayoshi Mai, Tetsuro Kubota, Masaki Kitajima, Yusuke Tanigawara, Yoshito Komatsu, Tetsuya Toge, Shigetoyo Saji

Research output: Contribution to journal › Article › peer-review

9 Citations (Scopus)

Abstract

A randomized phase II clinical trial has been designed and started in the Japanese Foundation for Multidisciplinary Treatment of Cancer (JFMC) to select the better regimen between tailored CPT-11 + S-1 and the standard S-1 treatment for advanced or recurrent gastric cancer as the first line chemotherapy. Selection of the better treatment for general clinical practice in this clinical trial will lead to a more precise assignment of a promising regimen for a future phase III randomized trial, placing continuous 5-FU infusion as the reference arm. In this trial, subsidiary pharmacokinetic analysis for the tailored dose arm is also proposed. In order to continue chemotherapy for a long time and to obtain longer survival, our study design for the tailored therapy could be exploited, especially in the field of general clinical practice.

Original language	English
Pages (from-to)	342-345
Number of pages	4
Journal	Japanese journal of clinical oncology
Volume	34
Issue number	6
DOIs	https://doi.org/10.1093/jjco/hyh067
Publication status	Published - 2004 Jun 1
Externally published	Yes

Keywords

CPT-11
Gastric cancer
S-1
Tailored dose chemotherapy

ASJC Scopus subject areas

Oncology
Radiology Nuclear Medicine and imaging
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1093/jjco/hyh067

Cite this

Takahashi, Y., Sakamoto, J., Takeuchi, T., Mai, M., Kubota, T., Kitajima, M., Tanigawara, Y., Komatsu, Y., Toge, T., & Saji, S. (2004). A randomized phase II clinical trial of tailored CPT-11 + S-1 vs S-1 in patients with advanced or recurrent gastric carcinoma as the first line chemotherapy. Japanese journal of clinical oncology, 34(6), 342-345. https://doi.org/10.1093/jjco/hyh067

A randomized phase II clinical trial of tailored CPT-11 + S-1 vs S-1 in patients with advanced or recurrent gastric carcinoma as the first line chemotherapy. / Takahashi, Yutaka; Sakamoto, Junichi; Takeuchi, Tetsuo et al.
In: Japanese journal of clinical oncology, Vol. 34, No. 6, 01.06.2004, p. 342-345.

Research output: Contribution to journal › Article › peer-review

Takahashi, Y, Sakamoto, J, Takeuchi, T, Mai, M, Kubota, T, Kitajima, M, Tanigawara, Y, Komatsu, Y, Toge, T & Saji, S 2004, 'A randomized phase II clinical trial of tailored CPT-11 + S-1 vs S-1 in patients with advanced or recurrent gastric carcinoma as the first line chemotherapy', Japanese journal of clinical oncology, vol. 34, no. 6, pp. 342-345. https://doi.org/10.1093/jjco/hyh067

@article{a6671640dae640f6b5efe96f225d2253,

title = "A randomized phase II clinical trial of tailored CPT-11 + S-1 vs S-1 in patients with advanced or recurrent gastric carcinoma as the first line chemotherapy",

abstract = "A randomized phase II clinical trial has been designed and started in the Japanese Foundation for Multidisciplinary Treatment of Cancer (JFMC) to select the better regimen between tailored CPT-11 + S-1 and the standard S-1 treatment for advanced or recurrent gastric cancer as the first line chemotherapy. Selection of the better treatment for general clinical practice in this clinical trial will lead to a more precise assignment of a promising regimen for a future phase III randomized trial, placing continuous 5-FU infusion as the reference arm. In this trial, subsidiary pharmacokinetic analysis for the tailored dose arm is also proposed. In order to continue chemotherapy for a long time and to obtain longer survival, our study design for the tailored therapy could be exploited, especially in the field of general clinical practice.",

keywords = "CPT-11, Gastric cancer, S-1, Tailored dose chemotherapy",

author = "Yutaka Takahashi and Junichi Sakamoto and Tetsuo Takeuchi and Masayoshi Mai and Tetsuro Kubota and Masaki Kitajima and Yusuke Tanigawara and Yoshito Komatsu and Tetsuya Toge and Shigetoyo Saji",

note = "Funding Information: Research grants from the JFMC.",

year = "2004",

month = jun,

day = "1",

doi = "10.1093/jjco/hyh067",

language = "English",

volume = "34",

pages = "342--345",

journal = "Japanese journal of clinical oncology",

issn = "0368-2811",

publisher = "Oxford University Press",

number = "6",

}

TY - JOUR

T1 - A randomized phase II clinical trial of tailored CPT-11 + S-1 vs S-1 in patients with advanced or recurrent gastric carcinoma as the first line chemotherapy

AU - Takahashi, Yutaka

AU - Sakamoto, Junichi

AU - Takeuchi, Tetsuo

AU - Mai, Masayoshi

AU - Kubota, Tetsuro

AU - Kitajima, Masaki

AU - Tanigawara, Yusuke

AU - Komatsu, Yoshito

AU - Toge, Tetsuya

AU - Saji, Shigetoyo

N1 - Funding Information: Research grants from the JFMC.

PY - 2004/6/1

Y1 - 2004/6/1

N2 - A randomized phase II clinical trial has been designed and started in the Japanese Foundation for Multidisciplinary Treatment of Cancer (JFMC) to select the better regimen between tailored CPT-11 + S-1 and the standard S-1 treatment for advanced or recurrent gastric cancer as the first line chemotherapy. Selection of the better treatment for general clinical practice in this clinical trial will lead to a more precise assignment of a promising regimen for a future phase III randomized trial, placing continuous 5-FU infusion as the reference arm. In this trial, subsidiary pharmacokinetic analysis for the tailored dose arm is also proposed. In order to continue chemotherapy for a long time and to obtain longer survival, our study design for the tailored therapy could be exploited, especially in the field of general clinical practice.

AB - A randomized phase II clinical trial has been designed and started in the Japanese Foundation for Multidisciplinary Treatment of Cancer (JFMC) to select the better regimen between tailored CPT-11 + S-1 and the standard S-1 treatment for advanced or recurrent gastric cancer as the first line chemotherapy. Selection of the better treatment for general clinical practice in this clinical trial will lead to a more precise assignment of a promising regimen for a future phase III randomized trial, placing continuous 5-FU infusion as the reference arm. In this trial, subsidiary pharmacokinetic analysis for the tailored dose arm is also proposed. In order to continue chemotherapy for a long time and to obtain longer survival, our study design for the tailored therapy could be exploited, especially in the field of general clinical practice.

KW - CPT-11

KW - Gastric cancer

KW - S-1

KW - Tailored dose chemotherapy

UR - http://www.scopus.com/inward/record.url?scp=6044267545&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=6044267545&partnerID=8YFLogxK

U2 - 10.1093/jjco/hyh067

DO - 10.1093/jjco/hyh067

M3 - Article

C2 - 15333687

AN - SCOPUS:6044267545

SN - 0368-2811

VL - 34

SP - 342

EP - 345

JO - Japanese journal of clinical oncology

JF - Japanese journal of clinical oncology

IS - 6

ER -

A randomized phase II clinical trial of tailored CPT-11 + S-1 vs S-1 in patients with advanced or recurrent gastric carcinoma as the first line chemotherapy

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this